Prof. Dr. Wagner José Fávaro is a Professor of Human Anatomy at the University of Campinas (UNICAMP), where he has built an outstanding academic career, earning his Masters, Ph.D., Postdoctoral, and, in 2022, the title of Associate Professor (Livre-Docente) in Urogenital System Anatomy. A specialist in Uropathology, Urogenital Carcinogenesis, Nanomedicine, and Drug Development, his scientific contributions are recognized both nationally and internationally.He is a member of prestigious international scientific societies, including the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), and the Society for ImmunoTherapy of Cancer (SITC). In Brazil, he is a Full Member of the Brazilian Society of Nanomedicine. From 2017 to 2020, he served on the CAPES Four-Year Evaluation Committee for Medicine III, contributing to the advancement and evaluation of scientific research in Brazil.In the business field, he is a Co-Founder of NANOIMMUNOTHERAPY PHARMA LTDA, an innovative company dedicated to developing drugs for human and veterinary use, bridging academic research and technological innovation. At UNICAMP, he leads the research group "Nanomedicine Applied to Immuno-Oncology and Inflammatory Diseases", registered with the Brazilian National Research Council (CNPq), and coordinates the Center for Immunotherapy and Inflammatory Diseases (CIDI), established based on discoveries related to the OncoTherad immunotherapy.Among his accomplishments, the development of OncoTherad (MRB-CFI-1) stands out as the first 100 Brazilian immunotherapy created in a public university. After 15 years of research in urogenital carcinogenesis and nanotechnology, OncoTherad has shown significant efficacy in reducing solid tumors in preclinical and clinical studies, marking a milestone in immunotherapy for cancer treatment. This scientific breakthrough has resulted in multiple patents, both in Brazil and internationally, as well as registered trademarks.Prof. Dr. Fávaro has also made significant contributions to the dissemination of academic knowledge. He created the "Anatomia Unicamp" YouTube channel, a widely used educational resource for students and healthcare professionals. He has published numerous scientific articles in high-impact journals and book chapters in cutting-edge fields such as nanomedicine and oncology. His scientific and technological innovations have earned him prestigious awards, including the Diploma of Health Merit (2023), the SBOC Science Award (2021), the UNICAMP Inventors Award (2020), the Newton Prado Medal (2018), the Prof. Nelson Rodrigues Netto Jr. Urology Award (2018), the INOVA UNICAMP Award (2018), and the IV Octavio Frias de Oliveira Award (2013).Furthermore, his international contributions include coordinating high-impact projects, such as the International Research and Development Cooperation Project with Slovenia, funded by the Ministry of Science, Technology, Innovation, and Communications (MCTIC) in 2014, and serving as the official representative of the Ministry of Science and Technology at the European consortium NANoREG, focused on regulatory protocols for nanomaterials. These activities underscore his position as a scientist with global impact.Recognized for his scientific relevance, he ranks among the Top 10,000 most influential researchers in Brazil and Latin America according to the Alper-Doger (AD) Scientific Index 2024-2025, solidifying his leadership in translational research, innovation, and the training of future generations of researchers. (Source: Lattes Curriculum)
| Articles published in Pesquisa FAPESP Magazine about the researcher: |
| Mensajeros poderosos |
| More itemsLess items |
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Immunotherapy with Bacillus Calmette-Guerin (BCG) has been the gold standard treatment for non-muscle invasive bladder cancer (NMIBC) for almost half a century. However, many high-risk disease patients experience recurrence, including those who progress and eventually do not respond to BCG. For decades, apart from radical cystectomy, few therapeutic options existed for this high-risk popu…
Bladder cancer (BC) represents the second most common malignant disease of the urinary tract, and one of the neoplasms that have the highest costs for the Unified Health System. The primary treatment of non-muscle invasive bladder cancer (NMIBC) is based on surgical treatment using transurethral resection, followed by intravesical immunotherapy with Bacillus Calmette-Guérin (BCG), to redu…
Bladder cancer (BC) is the second most common malignant disease of the urinary tract, and one of the most costly neoplasms for the Unified Health System. The primary treatment of non-muscle invasive bladder cancer (NMIBC) is based on transurethral resection, followed by intravesical immunotherapy with Bacillus Calmette-Guérin (BCG), to decrease recurrence and prevent tumor progression. Ho…
Understanding how cancer cells are able to ensure a positive energetic balance and associate it with anabolic processes is vital to the development of effective therapies against cancer. The neoplastic cells face two major challenges: answer the bioenergetic and biosynthetic demands of increased growth and cellular proliferation and implement metabolic adaptation strategies to survive the…
(Only some records are available in English at this moment)
The development and progression of cancer are characterized by a unique reprogramming of energy metabolism, essential to sustain the highly proliferative nature of neoplastic cells. The study of energy metabolism in neoplastic cells is fundamental to understanding how these cells maintain their rapid growth and proliferation, especially under adverse conditions of nutrient and oxygen avai…
Nearly half a century the immunotherapy with Bacillus Calmette-Guerin (BCG) has been the gold standard treatment for non-muscle invasive bladder cancer (NMIBC). However, many patients with high-risk disease experience recurrence, including those who progress and eventually become unresponsive to BCG. For decades, apart from radical cystectomy, few therapeutic options existed for this at-r…
Stretch marks are common skin lesions, resulting from stretching or distension of the skin, due to the rupture of elastic and collagen fibers. Its treatment is quite challenging, whether in the prophylactic or preventive form and so far, no therapy is sufficiently effective and with minimal adverse effects. In this sense, it is necessary to develop new therapeutic approaches for the treat…
Nearly half a century the immunotherapy with Bacillus Calmette-Guerin (BCG) has been the gold standard treatment for non-muscle invasive bladder cancer (NMIBC). However, many patients with high-risk disease experience recurrence, including those who progress and eventually become unresponsive to BCG. For decades, apart from radical cystectomy, few therapeutic options existed for this at-r…
(Only some records are available in English at this moment)
Ovarian cancer (OC) ranks fifth among cancer deaths in women and remains the deadliest of all gynecological cancers. The OC poor outcomes highlight the need to develop new clinical approaches and especially a better understanding of this disease. Molecular analyzes have shown significant genetic heterogeneity among the OC subtypes and the importance of an assessment of underlying molecula…
| 1 / 1 | Ongoing research grants |
| 5 / 5 | Completed research grants |
| 1 / 1 | Ongoing scholarships in Brazil |
| 37 / 35 | Completed scholarships in Brazil |
| 1 / 1 | Completed scholarships abroad |
| 45 / 43 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID